Abstract
In order to understand the clinical research progress of epidermal growth factor receptor inhibitors, the author reviewed the related research and literature report.It considers that cetuximab is mainly used for colorectal cancer without KRAS gene mutations, and trastuzumab is mainly used for breast cancer and gastric cancer with over expression of HER-2, and gefitinib and icotinib is mainly used for non-small cell lung adenocarcinoma with EGFR gene mutations.The above points of view can provide reference for the clinical application of these drugs. Key words: Epidermal growth factor receptor inhibitor; Clinical research; Overview
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
